Literature DB >> 8523990

Assessment of serum antibodies in patients with rapidly progressive sensorineural hearing loss and Menière's disease.

S Gottschlich1, P B Billings, E M Keithley, M H Weisman, J P Harris.   

Abstract

The immunoreactivity of sera from patients with rapidly progressive sensorineural hearing loss (SNHL) or Menière's disease with bovine inner ear material was determined using the Western blot technique. Patients with other otologic conditions, autoimmune disorders, or arthritic disorders and age-matched randomly chosen patients with no hearing complaints served as controls. Twenty-two percent of the patients with bilateral rapidly progressive SNHL and 30% of the patients with Menière's disease had antibodies that reacted with a 68 kd antigen in the inner ear material. In the control groups, the incidence of reactivity was 5.0% (P < .001). When the results of this study were compiled with data collected previously, it was found that of 279 patients with bilateral rapidly progressive SNHL, 90 (32%) were positive with the 68 kd protein. Thus, the anti-68 kd antibody may provide a good marker for an immune etiology of these patients' hearing loss.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8523990     DOI: 10.1288/00005537-199512000-00016

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  17 in total

1.  A gene for fluctuating, progressive autosomal dominant nonsyndromic hearing loss, DFNA16, maps to chromosome 2q23-24.3.

Authors:  K Fukushima; N Kasai; Y Ueki; K Nishizaki; K Sugata; S Hirakawa; A Masuda; M Gunduz; Y Ninomiya; Y Masuda; M Sato; W T McGuirt; P Coucke; G Van Camp; R J Smith
Journal:  Am J Hum Genet       Date:  1999-07       Impact factor: 11.025

2.  Antibodies to inner ear antigens in Meniere's disease.

Authors:  L Riente; F Bongiorni; A Nacci; P Migliorini; G Segnini; A Delle Sedie; F Ursino; S Tommasi; B Fattori
Journal:  Clin Exp Immunol       Date:  2004-01       Impact factor: 4.330

3.  Frequency-specific association of antibodies against heat shock proteins 60 and 70 with noise-induced hearing loss in Chinese workers.

Authors:  Miao Yang; Jianru Zheng; Qiaoling Yang; Huiling Yao; Yongwen Chen; Hao Tan; Changzheng Jiang; Feng Wang; Meian He; Sheng Chen; Qingyi Wei; Robert M Tanguay; Tangchun Wu
Journal:  Cell Stress Chaperones       Date:  2004       Impact factor: 3.667

4.  Serum antibodies against membranous labyrinth in patients with "idiopathic" bilateral vestibulopathy.

Authors:  V Arbusow; M Strupp; M Dieterich; W Stöcker; A Naumann; P Schulz; T Brandt
Journal:  J Neurol       Date:  1998-03       Impact factor: 4.849

5.  Systemic immunity influences hearing preservation in cochlear implantation.

Authors:  Melanie Souter; Hayden Eastwood; Paul Marovic; Gordana Kel; Sarin Wongprasartsuk; Allen F Ryan; Stephen John O'Leary
Journal:  Otol Neurotol       Date:  2012-06       Impact factor: 2.311

6.  Pseudonystagmus--clinical features and quantitative characteristics.

Authors:  Aasef G Shaikh; Stephen Reich; David S Zee
Journal:  Nat Rev Neurol       Date:  2010-08-03       Impact factor: 42.937

7.  Murine autoimmune hearing loss mediated by CD4+ T cells specific for inner ear peptides.

Authors:  C Arturo Solares; Andrea E Edling; Justin M Johnson; Moo-Jin Baek; Keiko Hirose; Gordon B Hughes; Vincent K Tuohy
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

8.  Rheumatoid factor and hearing loss.

Authors:  V Ashok Murthy; J Mohan Kumar
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2011-12-03

Review 9.  Idiopathic sensorineural hearing disorders in adults--a pragmatic approach.

Authors:  David L George; Sagun Pradhan
Journal:  Nat Rev Rheumatol       Date:  2009-08-04       Impact factor: 20.543

Review 10.  The diagnosis of autoimmune inner ear disease: evidence and critical pitfalls.

Authors:  Roberto Bovo; Andrea Ciorba; Alessandro Martini
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-09-06       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.